glp-1 or metformin Comparing Glucagon‐like peptide‐1 receptor agonists versus in drug‐naive patients: A nationwide cohort study Comparison of type 2 diabetes

The glucagon-like peptide (GLP)-1 agonists weight loss drugs market is on a robust growth trajectory, expected to expand from $15.5 billion in 2025 to $18.02 billion in 2026, at a CAGR of 16.3%

Meyer and colleagues evaluated the antioxidant capacity of 15 commercially available green teas using CURPAC and ORAC, discovering that matcha, gunpowder, and bagged green teas had higher total phenolic content and stronger CUPRAC and ORAC antioxidant capacities compared to other teas (Salem et al., 2022)

It pairs CJC-1295 in its short-acting No-DAC form a growth-hormone-releasing hormone (GHRH) analogue with Ipamorelin, a selective growth hormone secretagogue

Lorenzon, Cell Biol